PhotoSonix Medical appoints former NeoStrata CEO Mark D. Steele to Board of Directors
PhotoSonix Medical's CLENS™ System is an entirely new drug-free approach for treating acne at home without antibiotics.
FORT WASHINGTON, Pa., Feb. 16, 2017 /PRNewswire/ -- PhotoSonix Medical, Inc. a medical technology company transforming the treatment of acne, announced that Mark D. Steele has joined the Company's Board of Directors. Mr. Steele joins a distinguished Board of industry leaders in their pursuit to deliver a new level of efficacy to millions of patients who suffer from acne.
Mr. Steele is a 30-year veteran of the dermatology and consumer products industries. After senior management roles with Warner Lambert and Procter & Gamble, Steele most recently served as CEO of NeoStrata where he led the successful sale of the company to Johnson and Johnson. He also received the 2012 Ernst and Young Entrepreneur of the Year Award.
"Mark brings to PhotoSonix extensive operating and commercialization expertise with both a large company and small company perspective," said Adam Dakin, President & CEO of PhotoSonix. "We are honored to welcome him to our Board."
"PhotoSonix has developed a novel approach to the treatment of acne, a large market without many effective solutions. CLENS™ represents a new type of technology that could bring superior relief to millions of acne sufferers," said Steele. "The company's mission and science driven approach aligns with my passion for developing new dermatological solutions that deliver superior efficacy."
About PhotoSonix Medical
PhotoSonix's patented CLENS™ (Combined Light Energy and Non-focused ultraSound) combines ultrasound with blue light. The company's innovative platform targets biofilm-based infections which include acne. PhotoSonix is backed by Princeton Biopharma Capital Partners, Ben Franklin Technology Partners, and a sophisticated group of angel investors.
About Acne
Approximately 20 million patients in the US have acne severe enough to cause scarring. Expenditures on acne treatment in the US exceed $3 billion.
Note: The CLENS™ System is an investigational device and not available for commercial use in the United States.
| Company Information: |
|
SOURCE PhotoSonix Medical, Inc.
Share this article